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Gender-related differences in the pharmacological effects of drug are an emerging
topic. This review examines gender differences in both pharmacokinetic and
pharmacodynamic aspects of methadone, a long-acting opioid agonist that is
prescribed as a treatment for opioid dependence and the management of chronic pain.
Method: We performed a search in the Medline database from 1990 to 2014 in order
to find published literature related to gender differences in pharmacokinetics (PK) and
pharmacodynamics (PD) of methadone.
Results: None of the studies were carried out with the primary or secondary aim to
identify any gender differences in the pharmacokinetic profile of methadone. Importantly;
high inter-subjects variability in PK parameters was found also intra female population.
The reported differences in volume of distribution could be ascribed to the physiological
differences between men and women in body weight and composition, taking into
account that the dose of methadone was established irrespective of body weight of
patients (Peles and Adelson, 2006). On the other hand, the few studies present in
literature found no gender difference in some direct pharmacodynamic parameters.
Some reports have suggested that female gender is associated with an increased risk
for long-QT-related cardiac arrhythmias in methadone maintenance subjects.
Conclusion: Even though it may be too simplistic to expect variability only in one
parameter to explain inter-individual variation in methadone response, we believe that
a better knowledge of gender-related differences might have significant implications for
better outcomes in opioid dependence substitution therapy in women.
Keywords: gender differences, pharmacokinetics, pharmacodynamics, methadone treatment, toxicology
Introduction
The most recent statistical data in Europe (EMCDDA, 2014) indicate that females represent
roughly one in four drug users entering drug treatment and one in ﬁve deaths directly related
to drug use. However, although drug abuse is actually more common among men than women, a
progressively higher percentage of women in the world abuse both legal and/or illegal psychoactive
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drugs (Greenﬁeld et al., 2003; Becker and Hu, 2008), making
studies regarding gender diﬀerences in drug abuse extremely
relevant. Gender diﬀerences are referred to all phases of natural
history of drug abuse, i.e., initiation (Green et al., 2002; Becker
and Hu, 2008; Roy et al., 2011; Shand et al., 2011), escalation
(Hernandez-Avila et al., 2004), relapse, and treatment retention
(Lynch et al., 2002; Greenﬁeld et al., 2007; Niv and Hser, 2007;
Kennedy et al., 2013), as well as to adverse eﬀects (Gupta et al.,
2007), psychiatric comorbidity (Edokpolo et al., 2010; Sara et al.,
2013), and the class of drug of abuse (Simoni-Wastila et al., 2004;
Tetrault et al., 2008). Possible factors that could contribute to
gender diﬀerences are related to PK and PD variables.
Heroin abuse, despite the large increase in the 1990s,
decreased in the last decade, in spite of the ascending trends
in designer drugs consumers (Schifano et al., 2005), and
behavioral addictions (Martinotti et al., 2014). Unfortunately,
more recent data (NSDUH, 2010) indicate that in US the number
of heroin initiates was signiﬁcantly higher than the average
annual number between 2002 and 2008. Recent data from the
National Institute of Drug Abuse (NIDA, 2014) highlight the
unexpected association of prescription pain reliever abuse and
heroin, indicating the possible transition of experimenting with
non-medical prescription pain relievers through heroin abuse.
Data from 24 European countries also show an overall decrease
in the number of heroin clients. The number of ﬁrst-time heroin
clients increased from 2005 to 2007 and then decreased in 2011
(EMCDDA, 2014). In line with data on population of both
genders, the 2007 US National Survey on Drug Use and Health
indicates that the rate of current heroin use decreased between
2006 and 2007 from 0.06 to 0.02% per cent among females aged
12 or older.
Currently methadone (M) is the most commonly prescribed
replacement therapy for opioid dependence (only in the US
40% are female patients). In fact, recent data (EMCDDA, 2014)
indicate that in Europe buprenorphine is prescribed to about
20% of the substitution treatment opioid users, whereas almost
734.000 opioid users received substitution treatment in Europe
during 2012.
Although more than 15 years ago the FDA recommended
women may be increasingly included in clinical trials (U.S.
Food and Drug Administration, 1993), to date, gender diﬀerence
in pharmacological response to opioids is scarcely investigated
and only few clinical studies on opioid drugs (such as heroin,
opioid pain relievers, and the opioids in dependence treatment
M and buprenorphine) include gender as a factor. Increasing
the knowledge of pharmacological aspects related to opioid
substitution therapy drugs with relevance to female and male
diﬀerence is essential for a better understanding of factors that
inﬂuence opioid use among women, and might contribute to the
identiﬁcation and clinical use of gender-tailored therapy.
Aim of the Work
The goal of this review is to supply a selective summary of
the literature analyzing pharmacokinetic and pharmacodynamic
aspects of M with speciﬁc focus on data obtained in women.
We have also considered a limited number of studies including
only male subjects, with the aim to hypothesize some gender
diﬀerences, and also to underscore paucity of data.
Methods
We reviewed the literature and searched for published articles
related to gender diﬀerences in opioids pharmacokinetics
(PK) and pharmacodynamics (PD). The MEDLINE database
was examined from 1990 to 2014, using PubMed. Main key
words used were: methadone, opioid, substitution therapy,
pharmacology, PK, PD, sex/gender diﬀerence, individually, and
variously paired.
Methadone: PK and PD
Knowledge on PK and PD of M, in relation to diﬀerent
demographic characteristics (age, sex, pregnancy),
pathophysiology of patients (renal impairment), and also
drug interactions may contribute to the understanding of the
well known individual variability in response toM treatment; this
may in turn lead to an optimization of M therapy. Nevertheless
and despite the fact that women are more susceptible to some
of the adverse eﬀects of M, such as the lengthening of the QT
interval (Pearson and Woosley, 2005), the studies to investigate
M treatment were carried out mainly on samples from the male
population (Chopra et al., 2008).
Pharmacokinetics
Available literature between 1990 and 2014 related to the PK of
M with particular reference to any gender diﬀerence is listed in
Table 1.
Absorption and Distribution
As noted, M is characterized by high lipid solubility and protein
binding (Foster et al., 2000; Ferrari et al., 2004; Vazquez et al.,
2006). A study conducted to investigate the steady-state PK
of (R)- and (S)-methadone in an M maintenance population
(N = 18, 39%women) showed no gender-related eﬀect on plasma
concentration-time proﬁles after a multiple dosing regimen
for either (R)-methadone or (S)-methadone, neither on α1-
acid glycoprotein plasma concentration. Similarly, no eﬀect of
gender diﬀerence on initial Volume of distribution (Vd) in
a sample of 35 opiate users (M single dose: N = 23; 26 %
women; M multiple doses: N = 29; 45 % women was found
(Rostami-Hodjegan et al., 1999); however, in this study, since
M dose was in a range of 5–80 mg and plasma concentrations
were assessed and normalized to the dose of 70 mg using a
population-based pharmacokinetic approach, gender eﬀect on
dose-concentration relationship could not be evaluated. When
higher values of central Vd were found in female users (Rostami-
Hodjegan et al., 1999), this parameter was directly related to
sex diﬀerences in body weight. Accordingly, Wolﬀ et al. (1997)
in a sample of 21 males e 14 females reported that the Vd
of M was aﬀected by weight, but not by gender. On the
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TABLE 1 | Pharmacokinetics (PK) studies on methadone (M).
Reference Subjects N
(% female)
Subjects
category∗
Dosage regimen Dose
range (mg)
Biologic fluid of
determination
Sex difference (female)
Bart et al. (2014) 206 (39) I Multiple dosing 35–120 Plasma Sex data not published separately
Shiran et al. (2009) 88 (24) I Multiple dosing 15–130 Plasma = (R)-, (S)- and (R)-(S)-M plasma
C∗∗; = M clearance
Fredheim et al. (2007) 12 (42) II Multiple dosing 20–85 Plasma Sex data on M and EDDP∗∗∗
plasma C not published
separately
Hanna et al. (2005) 6 (1) I Multiple dosing
(no dose change greater
than 15 mg during the last
6 months)
20–170 Plasma
Sex data not published separately
Foster et al. (2004) 59 (39) I Multiple dosing
(no dose change for at least
2 months)
7.5–150 Plasma >Vd ∗∗∗∗
Preston et al. (2003) 27 (3) I Multiple dosing
(no dose change for at least
1 week)
35–80 Urine >EDDP C
Boulton et al. (2001) 8 (100) III Single dose 0.2 mg/Kg Plasma and urine High inter-subjects variability in
PK and PD parameters
Wolff et al. (2000) 35 (38) I Single dose 5–80 Plasma Difference in Vd not specified;
=M clearance
Foster et al. (2000) 18 (12) I Multiple dosing
(no dose change for at least
2 months)
7.5–130 Plasma = unbound fractions for (R)-M;
= a1-acid glycoprotein C;
= plasma C-time profiles for
either (R)- or (S)-M;
Rostami-Hodjegan
et al. (1999)
17 (6)
19 (13)
II
I
Single dose
Multiple dosing (Days 6–37)
5–80
5–80
Plasma =Vd
=Clearance
Preston et al. (2003) 27 (3) I Multiple dosing
(no dose change for at least
1 week)
35–80 Urine >Creatinine-corrected EDDP C
>non-significantly higher M C
=EDDP/M ratio
Eap et al. (1996) 22 (4.4) I Multiple dosing (R)-M
and subsequently (R, S)-M
120–160 Plasma Sex data not published separately
de Vos et al. (1995) 20 II Multiple dosing 10–225 Plasma <M clearance
∗ I = Methadone maintenance treatment, II = opiate users, III = drug free subjects, III = cancer patients.
∗∗ = Concentration.
∗∗∗ = 2-ethylidene-3,3-diphenylpyrrolidine.
∗∗∗∗ = Central volume of distribution (Vd).
contrary, Foster et al. (2004), identiﬁed gender and plasma a1-
acid glycoprotein concentration as signiﬁcant determinants of
apparent Vd of the central compartment (Vc/F). These data
are consistent with those observed by Rostami-Hodjegan et al.
(1999), which report that gender and weight (factors aﬀecting
body composition) were the two main covariates accounting for
33% of the inter-individual variability in M Vd at the steady-
state.
Metabolism
M biotransformation is largely mediated by CYP3A4 and
CYP2D6 (Eap et al., 2002), although CYP2B6 (Dennis et al.,
2014), CYP2C9, and CYP2C19 also appear to be involved, but
to a much lesser degree (Foster et al., 1999).
CYP3A4
CYP3A4 is responsible for M biotransformation in the major
metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine
(EDDP; Eap et al., 2002). Studies (Charlier et al., 2001; Eap
et al., 2002) aimed to identify the proper daily dose found a poor
correlation between M doses and M serum concentrations. In
another study (Boulton et al., 2001), performed on eight healthy
drug-free women, the authors showed a correlation between
urinary cortisol, area under the curve, and elimination of EDDP
(a metabolite of M). Recently, Shiran et al. (2009) in a study
conducted in a sample of 88 subjects (30 females) found that
CYP3A4 activity has a modest inﬂuence on M disposition.
The discrepancy between these results could be aﬀected by
several factors: conditions of concentration at steady state vs.
single dose, patients in methadone maintenance therapy (MMT)
vs. volunteers not taking chronic opiates.
To date inter-individual variations in the expression of
CYP3A4 are thought to be the main factor responsible for inter-
individual variability in M response (Li et al., 2008): indeed,
genetic polymorphism is considered the cause of high variability
of M blood concentrations for a given dose.
Moreover, CYP3A4 seems to be the main isoenzyme of
the CYP family showing signiﬁcant sex diﬀerences, since
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its expression in women is 1.5–2 times higher than in
men (Wolbold et al., 2003): the underlying mechanism is
presumably type transcriptional, linked to the mRNA. Notably,
CYP3A4 expression in the liver is controlled also by dynamic
interactions with transcription factors such as expression of
the ABCB1 (multidrug resistance 1 [MDR1]) gene encoding
the P-glycoprotein (P-gp) eﬄux transporter (Schuetz et al.,
2000). Since hepatic P-gp protein expression is twofold lower
in women than in men (Schuetz et al., 1995) this could
increase the intra-hepatic concentration of M and in turn its
more extensive metabolism. In this regard, pharmacogenetic
studies indicate that it is important to stratify by gender when
examining genotype/phenotype associations, especially for genes,
such as CYP3A4, which are diﬀerently expressed between genders
(Lamba et al., 2003, 2006).
CYP2D6
CYP2D6 contributes only to a small extent to the formation of
EDDP (Eap et al., 2002). It exhibits a high polymorphism: to date,
over 75 diﬀerent alleles have been identiﬁed (Borobia et al., 2009),
diﬀerently expressed among ethnic groups (Xie et al., 2001).
Clinical data regarding gender diﬀerences in the activity of
CYP2D6 are controversial. Some authors found no diﬀerences
among males and females, including poor metabolizers subjects
(Kashuba et al., 1998; Tamminga et al., 2001). Conversely, Labbé
et al. (2000) found in a sample of extensive metabolizers subjects,
that the metabolism of CYP2D6 substrate dextromethorphan, is
higher in women than in men, as conﬁrmed by Hägg et al. (2001).
Methadone maintenance therapy patients Shiran et al. (2003)
observed a lower activity of CYP2D6 (rated metabolic ratio of
dextromethorphan) in women; the results of this study revealed
the presence of a substantial genotype/phenotype discrepancy in
MMT patients, consistent with inhibition of CYP2D6. Authors
speculate that the chronic intake of M might induce inhibition
of CYP2D6, similarly, to the one observed in in vitro conditions
(Wu et al., 1993). This hypothesis could explain, according to the
authors, that the diﬀerence in activity observed in both genders
may result from possible diﬀerences between themselves in the
plasma concentration of M administered at the same dose. In any
case, in a more recent study involving 88 subjects (including 30
women), Shiran et al. (2009) evaluated the possible inﬂuences
of the activity of CYP2D6, 1A2, and 3A4 on the availability of
M, reporting that gender did not have a signiﬁcant inﬂuence,
along with other covariates such as CYP activity, weight, and
age, neither on the plasma concentration of M nor on its
clearance.
Excretion
M undertakes hepatic metabolism and renal excretion (Garrido
and Trocóniz, 1999). With respect to its hepatic elimination,
M has a restricted clearance or a low extraction ratio, while,
as a consequence of its chemical properties, urine pH has
been shown to inﬂuence the excretion of M (Inturrisi et al.,
1987). To our knowledge, there are no studies that have
shown gender diﬀerences in the excretion of M; however, it is
useful to point out that recently Poggio et al. (2009) observed
that females had slightly but signiﬁcantly higher glomerular
ﬁltration rate (measured by 125I-iothalamate clearances) than
males after adjustment for body surface area, but there were no
diﬀerences due to race. Instead, Berg (2006) found no diﬀerence
in glomerular ﬁltration rate by clearance of para-aminohippuric
acid (PAH) between males and females, in a total of 122 potential
kidney donors (62 females).
To summarize, none of the studies was carried out with the
primary or secondary aim to identify any gender diﬀerences
in the pharmacokinetic proﬁle of M. Importantly, high inter-
subjects variability in PK parameters was found also intra female
population (Boulton et al., 2001) Anyway, when women are
included in clinical studies and sex data were analyzed separately
some signiﬁcant diﬀerences were detected.
The physiological diﬀerences between men and women in
body weight and composition (per cent of fat, plasma volume,
and organ blood ﬂow) could be evoked to explain diﬀerence in
Vd, taking into account dose M is established irrespective of
body weight of patients (Peles and Adelson, 2006). It can be
hypothesized that, in turn, changes in Vd may in turn aﬀect
both the levels of plasma concentration and the half-life, with
consequences on the eﬀect of drugs in terms of onset of action
and duration of eﬀects.
Pharmacodynamics
Clinical studies on M PK/PD relationship are listed in Table 2.
None of these studies has been conducted to primarily identify
a possible diﬀerence in M PD parameters in women compared
to men; in most of the studies gender data are not analyzed
separately. In a study conducted by Hiltunen et al. (1999),
no inﬂuence of gender was found on the interaction between
l-M plasma concentrations and subjective opiate withdrawal
scale (SOWS) of “negative” (irritability, disorientation, remorse,
sadness, and low psychomotor speed), and “positive” eﬀects
(feelings of alertness, calmness, patience, relaxation, cheerfulness,
carefreeness, and clear-thinking). Peles and Adelson (2006)
comparing gender outcome among 470 MMT patients (28%
women) found no gender diﬀerences in treatment retention,
stop in opiate abuse, and decrease in cocaine abuse. The
average M dose was almost the same between men and women
(131.1 ± 54.8; 132.3 ± 49.5 mg).
On the contrary in another study (Pérez de Los Cobos et al.,
2005) conducted on 169 patients (33 % women) to evaluate
satisfaction with treatment (dose adjustment, participation in
dosage regulation) it was found that female patients had more
positive opinions and a better satisfaction thanmales aboutM as a
medication. Accordingly, some authors (Green, 2006; Greenﬁeld
et al., 2007) observed that males were more expected to drop
out of outpatient drug-free programs, whereas females were more
likely to be considered in the low-retention group for outpatient
M treatment (Simpson et al., 1997). In a more recent study
aimed to ascertain gender and M maintenance dose inﬂuence
on naloxone response in volunteers, a signiﬁcant diﬀerence in
mean M doses was observed between males and females (when
body weight was considered; Chopra et al., 2008). These results
indicate that women on lower M maintenance doses might be
very sensitive to the dysphoric eﬀects of naloxone-induced opiate
withdrawal.
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TABLE 2 | Methadone (M) PK/PD relationship studies.
Reference Subjects
N (% female)
Subjects
Category∗
Dosage
regimen
Dose range
(mg)
PD effect Findings/
Comments
Hanna et al. (2005) 6 (16.6) I Repeated dose 20–170 mg/die Antinociception, mood
disturbance, respiration rate,
pupil size, withdrawal.
Highly significant differences in the
between- to within-subject
variability. Small subjects number
Maremmani et al.
(2005)
83 (24) I Repeated dose 10–600 mg/die QTc prolongation No correlation between QTc values
and M doses; no gender
differences in QTc values
Pearson and
Woosley (2005)
58 (59) I Repeated dose 29–1680 mg/die QTc prolongation and/or TdP Female gender as risk factor; QT
prolongation at therapeutic dose
Pérez de Los
Cobos et al. (2005)
165 (23) I Repeated dose
12–150 mg/die Patient M therapy satisfation Female gender more satisfied
Fisher et al. (2004) 6 (50) II Repeated dose 1-4 X 1-25 mg/die Antinociception Patients’ heterogeneous condition;
data not analyzed by gender; small
subjects number
Mitchell et al. (2004) 55 (38) I Repeated dose 7.5–300 mg/die Mood disturbance, respiration
rate, pupil size, heart rate,
blood pressure, withdrawal.
Gender data not published
separately; M AUC∗∗ not related to
PD responses, except for mood
disturbance and heart rate
Dyer et al. (2001) 18 (39) I Repeated dose 7.5–130 mg/die Mood disturbance Gender data not published
separately; M plasma
concentration inversely related to
mood disturbance
Boulton et al.
(2001)
8 (100) III Single dose 0.2 mg/Kg Pupil diameter Large inter-subject variability
Dyer et al. (1999) 18 (39)
I
Repeated dose 7.5–130 mg/die Withdrawal severity, Pain
threshold, Pupil diameter,
Respiratory rate
No differences between holders
and non-holders with respect to
gender
Gourevitch et al.
(1999) 18 (56) I Repeated dose 30–100 mg/die Withdrawal
Gender data not published
separately; no correlation between
self-reported symptoms of
withdrawal and trough plasma M
levels.
Hiltunen et al.
(1999)
50 (24) I Repeated dose 35–140 mg/die Objective and subjective
withdrawal scale in relation to
plasma M C∗∗∗
No gender differences on the
interaction between l-M plasma
concentrations and “negative” as
well as of ”positive” M effects
Inturrisi et al. (1990) 15 (27) II i.v. infusion
(180–270 min)
20–25 mg/hour
(loading dose)
Relationship between plasma
M C and PD effects (analgesia
and sedation)
Sex data not published separately
∗ I = Methadone maintenance treatment, II = Patients with cancer-related pain, III = healthy subjects.
∗∗ = Area under the curve.
∗∗∗ = Concentration.
It should, however, be noted that no pharmacodynamic
parameters were directly analyzed. Some studies have shown
a diﬀerence in μ-opioid binding between males and females.
Smith et al. (1998), using positron emission tomography (PET),
observed a higher μ-opioid binding in women in a number
of cortical and subcortical areas. Furthermore, gonadal steroid
hormones such as estrogenic states can inﬂuence μ-opioid
receptor density (related to opioid relative eﬃcacy) and signal
transduction (Smith et al., 1998). More recently Smith et al.
(2006) have demonstrated that a high-estrogen state is related
to area-speciﬁc increases in μ-opioid receptor availability, while
during the low estrogenic conditions signiﬁcant reduction in
endogenous opioid tone was observed at the level of thalamus,
nucleus accumbens, and amygdala. Age is another factor that can
contribute to μ-receptor occupancy. In fact, in postmenopausal
women the in vivo μ-opioid binding decreases to levels below
those of men (Zubieta et al., 1999).
Some studies (Drici and Clément, 2001; Pearson andWoosley,
2005), although not equivocally (Maremmani et al., 2005), have
suggested that female gender is associated with higher risk
for long-QT (LQT)-dependent cardiac arrhythmias in MMT
subjects. Reports to the FDA spontaneous reporting system
(however, considered an underestimation of the total number
of events) indicate that in a total of 5503 reports of adverse
events associated with M, 1.07 % noted the occurrence of QT
prolongation and TdP, and that 59% were females. Importantly,
the dosages for 29% of the cases were within the recommended
range for M maintenance treatment (60–100 mg/day), indicating
that pharmacodynamic variables, not pharmacokinetic, might
explain this cardiac eﬀect.
Frontiers in Pharmacology | www.frontiersin.org 5 June 2015 | Volume 6 | Article 122
Graziani and Nisticò Genders and methadone
Among the possible factors that can contribute to M cardiac
toxicity, there may be physiological diﬀerences in cardiac
conduction between genders: the baseline QTc of the post
puberty female is longer than that of males (Abi-Gerges et al.,
2004), suggesting that sex steroid hormones are implicated
in modulating cardiac repolarization; drugs like M blocking
cardiac voltage gated potassium channels, particularly the rapid
component (IKr) of the delayed rectiﬁer potassium current
(IK), may induce a prolongation of the QT interval (Drici and
Clément, 2001). In contrast, in a study (Maremmani et al., 2005)
conducted to assess the incidence of abnormal QTc interval
values in a population of subjects (20 females, 63 males) on
a long-term MMT (60–100 mg/die), gender diﬀerences in the
recorded QTc values were found not statistically signiﬁcant. It
should be noted, however, that the number of women enrolled in
the sample was not very high, as it has not been clariﬁed whether
the average M dose was lower in women than in men.
In summary, considering the above mentioned inter women
variability, the few studies present in literature found no
gender diﬀerence in some direct pharmacodynamic parameters
(withdrawal severity, pain threshold, pupil diameter, and
respiratory rate, as well as in the interaction between l-M plasma
concentration and its “negative”/“positive” eﬀects. However,
there is no consensus in the literature about gender diﬀerences
in treatment satisfaction and retention in M substitution
therapy. On the other hand, there is clear evidence of women’s
vulnerability to M cardiac adverse eﬀects that may be related to
gender-related physiological diﬀerences in cardiac conduction.
Conclusion
To date, data available on M PK and PD focuses primarily on
male subjects. Little is known about women or how the genders
compare. We hope that future studies will determine the exact
contribution of the gender factor to the inter-individual variation
of the pharmacology of M in patients. Even though it may
be too simplistic to expect variability only in one parameter
to explain inter-individual variation in M response, we believe
that a better understanding of gender-related diﬀerences might
have important implications for a better outcome in opioid
dependence substitution therapy in women.
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